Thermo Fisher Scientific, the world leader in serving science, and Cedars-Sinai, a leading nonprofit academic healthcare organization based in the US, have entered into a collaboration to develop a pathway to precision medicine through the development of robust, reliable and sensitive liquid chromatography mass spectrometry (LC-MS)-based workflows for clinical research applications.

Bringing together Thermo Fisher's leading LC-MS technology with the expert insights of Cedars-Sinai's physicians and clinical research scientists, this initiative aims to provide clinical research laboratories with specific and sensitive LC-MS-based workflows that will deliver increased confidence in data while detecting and analyzing novel or known protein-based biomarkers within biological matrices.

Through their joint commitment, Thermo Fisher and Cedars-Sinai aim to develop a pathway to a future that includes precision medicine by:

• Developing robust data acquisition strategies for global plasma protein profiling and peptide selective reaction monitoring (SRM) assays for the direct analysis of plasma with or without enrichment.
• Optimizing quantitative intact protein analysis methods for plasma using Thermo Scientific Q Exactive Orbitrap mass spectrometer technology.
• Assessing targeted protein workflows with Thermo Scientific's new generation Triple Quadrupole mass spectrometers for large quantitation assays within a Clinical Laboratory Improvement Amendments (CLIA) environment.